Colgate-Palmolive Company

Colgate-Palmolive Company (CL) Market Cap

Colgate-Palmolive Company has a market capitalization of $70.88B.

Price: $88.58

β–² 3.48 (4.09%)

Market Cap: 70.88B

NYSE Β· time unavailable

CEO: Noel R. Wallace

Sector: Consumer Defensive

Industry: Household & Personal Products

IPO Date: 1973-05-02

Website: https://www.colgatepalmolive.com

Colgate-Palmolive Company (CL) - Company Information

Market Cap: 70.88B|Sector: Consumer Defensive

Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Analyst Sentiment

77%
Strong Buy

From 20 Active Polls

1Y Forecast: $94.90

β–² +7.1% Potential Upside

Consensus Target Metrics

Low Bound

$79

Median

$100

High Bound

$102

Average

$95

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$94.90
β–² +7.13% Upside
Low Target
$79.00
-11% Risk
Median Target
$99.50
12% Mid
High Target
$102.00
15% Max
Consensus
Hold
19 / 45 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

πŸ“Š Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)70,88168,38063,58764,57673,41276,61874,33784,88578,314
Enterprise Value ($M)77,51975,01870,28771,71680,95583,77581,75392,08785,880
Price to Earnings Ratio (P/E)34.0526.46-429.6421.9624.7027.7625.1528.7926.78
Price/Earnings-to-Growth Ratio (PEG)β€”14.72-222.6853.456.10β€”β€”β€”β€”
Price to Sales Ratio (P/S)3.4112.8412.1612.5914.3715.6015.0416.8715.48
Price to Book Ratio (P/B)490.12471.591177.5475.44104.58211.07350.65195.14636.70
Price to Free Cash Flow Ratio (P/FCF)18.82112.2849.8358.3994.60160.9668.5182.1789.71
Enterprise Value to Sales (EV/Sales)β€”14.0913.4413.9815.8417.0616.5418.3016.98
Enterprise Value to EBITDA (EV/EBITDA)19.7957.18411.0458.9366.5271.7967.6877.2569.88
Debt to Equity Ratio1.6954.99147.939.8412.4822.7840.1519.3970.54

⚑ CL Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$88.58
Intrinsic Value$45.97
Market Alignment
Overvalued by 48.1%relative to calculated intrinsic value
9.00%
Exp: 1%1%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$2.96B
Perpetuity TV Value$55.68B
Discounted TV (PV)$23.52B
TV Weighting %57.5%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ COLGATE-PALMOLIVE (CL) β€” Investment Overview

🧩 Business Model Overview

Colgate-Palmolive produces and sells branded consumer productsβ€”primarily oral care (toothpaste, toothbrushes, mouthwash) and also personal care and home care categories in specific geographies. The company monetizes recurring consumer replenishment through a global distribution engine that relies on strong retailer relationships, category leadership, and efficient manufacturing. Demand is driven by habitual use of oral hygiene products, while performance depends on the ability to maintain shelf presence, manage trade promotion intensity, and control input and logistics costs.

πŸ’° Revenue Streams & Monetisation Model

Revenue is overwhelmingly product sales (largely transactional, but with a recurring consumption cadence). The margin structure is shaped by:

  • Gross margin and mix: category leadership and portfolio depth support price/mix resilience when promotions are moderated; premiumization within oral care typically carries better margin than basic SKUs.
  • Operating leverage: scale manufacturing and procurement efficiencies help absorb fixed costs; brand support and trade spend determine the sustainability of operating margins.
  • Channel execution: retailer-funded promotions and consumer-facing pricing actions influence volume and net revenue realization.

Overall monetisation is supported by consistent demand replenishment, while profitability is most sensitive to input costs (commodity-linked inputs), freight/energy, foreign exchange, and the level of promotional intensity required to defend or grow share.

🧠 Competitive Advantages & Market Positioning

Colgate’s moat is primarily rooted in scale/distribution leverage and private-label resistance within oral care and adjacent categories. While toothpaste is not a high switching-cost product in the strict behavioral economics sense, Colgate benefits from durable consumer habits, long-running brand trust, and retailer preference for predictable performance versus store brands.

  • Switching friction via product performance + habit: consumers repurchase based on perceived efficacy (e.g., sensitivity, cavity protection, whitening) and established routines, reducing churn relative to generic alternatives.
  • Distribution leverage: global manufacturing scale and established trade relationships support consistent in-store availability and effective category management.
  • Private-label resistance: private label competes more effectively in price-led segments; replicating branded performance claims, consumer acceptance, and retailer shelf confidence is typically harder and often less margin-friendly.
  • Marketing and innovation flywheel: product line extension and formulation improvements reinforce brand differentiation, supporting shelf space and limiting effective displacement.

COMPETITIVE BENCHMARKING: Key competitors include:

  • Procter & Gamble (P&G): a major oral care rival with strong power in branded toothpaste and toothbrush segments.
  • GlaxoSmithKline (GSK): competes through clinically positioned oral care lines (e.g., sensitivity-oriented propositions).
  • Unilever: competes in personal care and oral care in certain markets, with aggressive promotion strategies.

Colgate’s positioning emphasizes broad category leadership and portfolio depth across geographies, often pairing frequent consumer replenishment categories with disciplined execution in trade channels to protect share against larger multinationals and local/regional brands.

πŸš€ Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is driven less by a single product cycle and more by structural demand and share/portfolio mix effects:

  • Market expansion from rising oral hygiene awareness: incremental penetration and improved usage frequency in emerging markets supports unit growth.
  • Premiumization within oral care: shift toward differentiated variants (sensitivity, advanced protection, whitening) supports value growth even with mature category volumes.
  • Execution-led share gains: consistent supply, retailer programs, and effective packaging/formulation updates can take share without relying on major price increases.
  • Geographic scaling and channel deepening: broad footprint improves the ability to invest through cycles and defend shelf presence in high-velocity markets.

The business model benefits from durable consumption patterns, enabling management to target growth through mix and distribution strength rather than dependence on one-off demand shocks.

⚠ Risk Factors to Monitor

  • Promotional intensity and share defense economics: prolonged trade spending or consumer price discounting can pressure margins.
  • Input cost volatility and logistics: commodity-linked and energy-linked costs can compress gross margin if not offset by sourcing, mix, or pricing.
  • Foreign exchange translation: international revenue exposure can affect reported results and inventory cost flows.
  • Regulatory and ingredient constraints: labeling, formulation, and claims substantiation requirements can increase compliance costs and limit certain product propositions.
  • Channel and retailer concentration: bargaining power shifts can influence shelf access terms, slotting fees, and promotional funding.

πŸ“Š Valuation & Market View

The market generally values consumer staples brands like Colgate using earnings durability and free-cash-flow confidence rather than high growth assumptions. Common valuation frameworks include EV/EBITDA and P/E for steady compounders, with P/S used when investors emphasize revenue stability and margin trajectory. Key variables that tend to move the valuation multiple include:

  • Sustainable gross margin: ability to manage input costs and protect product mix.
  • Operating margin durability: discipline in trade spend and brand investment efficiency.
  • Volume vs. price mix: share gains and premiumization can support revenue quality.
  • Capital return capacity: consistent cash generation supports dividends and buybacks, which can anchor investor expectations.

πŸ” Investment Takeaway

Colgate-Palmolive is a durable consumer staples franchise with an investment case anchored in distribution scale, private-label resistance, and portfolio-driven differentiation within oral careβ€”categories supported by habitual, recurring consumption. The long-term opportunity is primarily derived from premiumization and geographic penetration, while the main downside risks stem from promotional pressure, cost volatility, and retailer/channel bargaining dynamics.


⚠ AI-generated β€” informational only. Validate using filings before investing.

πŸ“° Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for CL.

seekingalpha.comβ€’2026-06-03

Colgate-Palmolive Company (CL) Presents at 23rd annual dbAccess Global Consumer Conference Transcript

Colgate-Palmolive Company (CL) Presents at 23rd annual dbAccess Global Consumer Conference Transcript

businesswire.comβ€’2026-06-03

Colgate-Palmolive Launches Serving Smiles, a New Podcast Delivering Health Conversations Gen Z Actually Want to Have

NEW YORK--(BUSINESS WIRE)--Colgate-Palmolive, a global leader in health and hygiene, today announced the launch of Serving Smiles, a new video-first podcast designed to tackle health misinformation and simplify wellness for Gen Z. Hosted by actor, singer and content creator Pressley Hosbach and award-winning advocate, actor and podcaster Madison Tevlin, the series brings expert-backed clarity to a generation overwhelmed by wellness trends and conflicting health advice that can be found on socia.

zacks.comβ€’2026-05-27

Is Colgate Too Dependent on Pricing Actions for Revenue Growth?

CL balances pricing and volume growth as emerging markets and innovation support sales momentum.

fool.comβ€’2026-05-26

Market Crash: The 3 Best Dividend Stocks to Buy Right Now

Some people aren't trusting this market rally, which continues to move higher. Every portfolio should have some defensive plays in it in case of a market downturn.

fool.comβ€’2026-05-23

My 5 Favorite Dividend Stocks to Buy Right Now

Consumer staples companies tend to generate resilient cash flows because their products and services remain in demand across all economic environments. The strength of Dividend Kings and long-term growers comes from structural advantages.

businesswire.comβ€’2026-05-20

Colgate-Palmolive Webcasts Fireside Chat at the dbAccess Global Consumer Conference

NEW YORK--(BUSINESS WIRE)--Colgate-Palmolive (NYSE:CL) Chief Operating Officer, Americas, Shane Grant and Executive Vice President, M&A and Special Projects, John Faucher will participate in a fireside chat at the dbAccess Global Consumer Conference in Paris on Wednesday, June 3, 2026 at 8:45 am ET. Investors may access a live webcast of this fireside chat on Colgate's website at www.colgatepalmolive.com. For those unable to participate during the live webcast, a recorded version of the web.

zacks.comβ€’2026-05-15

Why Colgate's Innovation Strategy Is Fueling Market Share Gains

CL's innovation strategy is driving market share gains as premium launches, pricing and science-based products support growth across oral care and pet nutrition.

247wallst.comβ€’2026-05-13

Prediction: Colgate-Palmolive Will Jump 20% This Year

Colgate-Palmolive (NYSE:CL | CL Price Prediction) is exactly the kind of name investors hunt for when the macro picture gets murky.

zacks.comβ€’2026-05-13

OLLI vs. CL: Which Stock Is the Better Value Option?

Investors interested in stocks from the Consumer Products - Staples sector have probably already heard of Ollie's Bargain Outlet (OLLI) and Colgate-Palmolive (CL). But which of these two companies is the best option for those looking for undervalued stocks?

zacks.comβ€’2026-05-12

Is Procter & Gamble's Baby Care Slump Dragging Overall Growth?

PG's U.S. Baby Care slump remains a weak spot, but strong global growth and targeted investments suggest it is a fixable issue, not a long-term drag.

seekingalpha.comβ€’2026-05-10

Colgate-Palmolive: Too Expensive For A Defensive Firm

Colgate-Palmolive delivered 8% sales growth in Q1 2026, but EPS declined 6%, warranting a conservative hold rating. I see organic growth of just 2.9%, with North America sales falling due to increased toothpaste competition and margin compression. FX tailwinds drove significant growth in Latin America, EMEA, and APAC, raising concerns about sustainability if currency trends reverse.

fool.comβ€’2026-05-08

The 2 Best Consumer Staples Stocks to Buy and Hold for Decades

Companies like Procter & Gamble and Colgate-Palmolive have embedded themselves so deeply into daily habits that buying their products stops feeling like a decision at all. Their growth narratives are less about convincing people to switch and more about scaling trust and upgrading within it.

247wallst.comβ€’2026-05-04

JPMorgan Lifts Colgate Price Target to $96: Why Emerging Markets Are Powering the Defensive Trade

Colgate-Palmolive (NYSE:CL | CL Price Prediction) stock picked up a fresh price target raise from JPMorgan on Monday, May 4, with the firm lifting its target to $96 from $95 while maintaining its Overweight rating.

seekingalpha.comβ€’2026-05-02

Colgate-Palmolive: A Resilient Dividend King Navigating A Tougher Environment

Colgate-Palmolive remains a Buy, supported by resilient fundamentals, an attractive and still sustainable dividend yield while they hold the Dividend King status, and prudent valuation amid macro and geopolitical headwinds. CL posted solid Q1 results, with 8.4% net sales growth, robust free cash flow, and reaffirmed 2026 sales and EPS growth guidance despite Iran-driven margin pressures. Rising input and logistics costs, driven by the Iran conflict, are expected to pressure gross margins, but CL's strong cash flows support ongoing shareholder returns.

gurufocus.comβ€’2026-05-02

Colgate-Palmolive Co (CL) Q1 2026 Earnings Call Highlights: Strong Growth Amidst Cost Challenges

Organic Sales Growth: Accelerated from the fourth quarter, driven by improved volume performance, particularly in Asia Pacific.Volume and Pricing Growth: Achie

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"Headline (2026-03-31, Q1): Revenue $5.324B (+2.0% QoQ; +8.4% YoY). Net income $646M (vs -$37M in Q4; +6.0% QoQ; +7.0% YoY) and EPS $0.81 (vs -$0.046 in Q4; +7.8% QoQ; +5.9% YoY). Profitability improved: gross margin was ~60.6% (slightly up vs Q4 and consistent vs prior-year), operating margin increased to 21.7% (up from 20.6% in Q4), and net margin improved to 12.1% (from -0.7% in Q4). Over the last four quarters, the business swung from a Q4 loss to strong seasonal rebound. Operating cash flow was $747M, generating free cash flow of $609M. Despite returning cash through buybacks (-$306M) and dividends (-$417M), liquidity rose slightly (cash at quarter-end $1.335B). Balance sheet leverage remains heavy (total debt ~$7.97B; net debt ~$6.64B), but interest coverage is strong (~18.6x), supporting dividend capacity. Total shareholder return signals are mixed: the stock is down over 1Y (-8.21%) with a small dividend yield (~0.61%). No strong 1-year momentum boost (>20%) is evident, and valuation indicators still look demanding (high P/E)."

Revenue Growth

Positive

Q1 2026 revenue rose to $5.324B (+2.0% QoQ from Q4 and +8.4% YoY from Q1 2025), indicating steady top-line momentum heading into the year.

Profitability

Good

Net income rebounded to $646M versus -$37M in Q4 and was up +7.0% YoY. Net margin improved to 12.1% (from -0.7% in Q4), with operating margin up to 21.7%.

Cash Flow Quality

Positive

Operating cash flow was $747M and free cash flow $609M. Buybacks (-$306M) and dividends (-$417M) were sizable, but liquidity increased modestly; cash flow supports shareholder returns.

Leverage & Balance Sheet

Caution

Leverage remains high (total debt ~$7.97B; net debt ~$6.64B) and equity is small on reported figures, but interest coverage is strong (~18.6x), reducing near-term refinancing risk.

Shareholder Returns

Fair

Dividend yield is low (~0.61%). Price performance is negative over 1Y (-8.21%), so total return is not strongly positive; buybacks help but momentum is muted.

Analyst Sentiment & Valuation

Neutral

Market price ($85.81) sits below the consensus target ($94.9), implying upside. However, valuation multiples remain elevated, limiting the score.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Colgate-Palmolive started 2026 with accelerating organic volume growth, led by emerging markets and Asia Pacific, including improving execution at Hawley & Hazel. Management emphasized advertising ROI and RGM discipline, sustaining brand investment despite sluggish category demand globally. The primary financial pressure is gross margin: guidance reflects embedded cost inflation with oil assumed around $110 and ~$300M additional raw materials/logistics impact (including logistics up nearly 10%). Tariffs are a key North America driver, with Q1 comparisons against minimal prior-year tariffs and normalization expected as the year progresses. Despite margin headwinds, EPS guidance confidence remains supported by RGM productivity and other cost flexibility (including SGPP productivity and structural simplification tied to the $200M–$300M savings target ending 2028). North America is the clearest execution risk, but management expects sequential improvement as shelf/reset timing issues clear and innovation ramps. Hill’s momentum remains a bright spot even as dry dog lags. Sentiment is mixed due to margin/tariff risk versus strong volume and emerging-market resilience.

AI IconGrowth Catalysts

  • Emerging markets acceleration with Asia Pacific as key driver; broad-based volume growth across almost all divisions and categories (except sluggish categories overall).
  • Hawley & Hazel execution improvements in Asia (dual tube technology/innovation, improved omnichannel execution including Douyin).
  • RGM (pricing/value actions) plus advertising-funded volume share gains in emerging markets and Latin America.
  • Innovation-led growth expansion across price points in emerging markets; premium opportunity alongside lower/mid-pricepoint initiatives.
  • Hill’s strong momentum: 4.8% organic volume+price ex private label ex private label at total, with Science Diet and Prescription Diet delivering double-digit growth in targeted areas.

Business Development

  • Hawley & Hazel (Asia Pacific business) intervention strategy referenced as driving improving execution; no named external partner provided.
  • Hill’s distribution gains tied to retailers: shelf space gaining attributed to innovation growth (retailer relationship improvement referenced; no named retailer).
  • Mentioned omnichannel execution on Douyin (platform partnership referenced implicitly via channel execution).

AI IconFinancial Highlights

  • Organic sales growth guidance maintained at 1% to 4% for full year despite pressured gross margins.
  • Gross margin pressure guidance change attributed to embedded cost inflation and tariff impacts; management explicitly states margins likely down for the year.
  • Embedded macro assumptions: oil roughly $110 for the balance of the year; incremental $300 million impact across raw materials and logistics (including logistics in the number).
  • Incremental cost detail: $300 million additional raw materials/logistics impact (roughly 2/3 raw materials, 1/3 logistics). Logistics costs up nearly 10% (ocean and land freight).
  • Oil-byproduct spend assumptions: resins, petrochemicals, fats and oils expected up more than 20% YoY for the full year.
  • North America gross margin pressure attributed to tariffs: year-over-year comparison versus prior year with minimal tariffs; tariff impact expected to lessen as year progresses.
  • Private label pet food exit impacts: private label 260 bps negative, tapering to 20-30 bps negative impact in Q2; expected to be out by back half of year.

AI IconCapital Funding

    AI IconStrategy & Ops

    • Strategic growth and productivity program update: $200 million to $300 million annualized savings target; majority expected in 2027 and 2028; not an extension (still expected to complete end of 2028).
    • Savings to fund 2030 strategy investments (capabilities/innovation) and bottom-line contribution; intent to drive consistent compounded dollar-based EPS growth.
    • Operational structure changes to reduce complexity for an β€œagile company” designed for omnichannel environment.
    • RGM productivity across the P&L and other productivity initiatives outside SGPP; productivity expected to impact both cost line and SG&A flexibility.

    AI IconMarket Outlook

    • Full-year organic sales growth guidance maintained at 1% to 4%.
    • Management expects North America sequential improvement and margin pressure normalization as tariffs normalize through the year.
    • Private label negative impact taper: 260 bps (Q1) β†’ 20-30 bps (Q2) β†’ out by back half of 2026.

    AI IconRisks & Headwinds

    • Significant increases in raw material and packaging costs built into guidance, pressuring gross margin.
    • Tariff headwind concentrated in North America; Q1 lapping benefited prior year minimal tariffs, while year-over-year impact expected to be less going forward.
    • Consumer/environment uncertainty: oil location and interest rates; category volumes still β€œsluggish” globally.
    • North America competition: competitor spending more on couponing to drive volume; Hill’s category dry dog segment slipping.

    Q&A: Analyst Interest

    • Cost inflation embedded in guidance: Management quantified oil at ~$110 average for remainder of year, with ~$300M incremental raw materials/logistics impact (2/3 raw, 1/3 logistics), logistics up nearly 10%, and oil-byproducts spend up >20% YoY; RGM productivity offsets maintained.
    • North America recovery plan: Management expects sequential volume and market-share improvement; interventions include brand interventions, accelerated innovation, RGM, improved execution, and better promotion strategy with key retailers; shelf resets and new product shipments arriving late dampened early-quarter volume, with acceleration in exiting quarter and second half.
    • Private label pet food exit + Hill’s traction: Management stated private label created a 260 bps negative headwind in Q1, tapering to 20–30 bps in Q2 and exiting by back half of year; Hill’s grew 4.8% organic ex private label, with Prescription Diet double-digit in targeted indications and broad channel/segment share gains.

    Sentiment: MIXED

    Note: This summary was synthesized by AI from the CL Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

    πŸ“‹ Official Regulatory 10-K / 10-Q SEC Filings

    Direct authenticated documentation links to audited SEC database reports for CL.

    SEC EDGAR Live Feed
    No recent 10-K available.
    No recent 10-Q available.
    Loading financial data and tables...
    πŸ“

    SEC Filings (CL)

    Β© 2026 Stock Market Info β€” Colgate-Palmolive Company (CL) Financial Profile